The topline data readout was promising, just as being selected by the NIH for the ACTIV5 trial and uplisting to NASDAQ were promising. But that is not revenue-producing news, and without that type of news, we cannot maintain momentum.
The EUA should change that. Concurrently announcing receipt of a stockpiling purchase order from the US government, etc., etc., will finally be the fuel that lights our rocket into the stratosphere.
If the company had offered me the chance to buy at $18.50 before I bought in the market above that price, I would have jumped on it. I hope they keep that in mind if it becomes necessary to max out our shelf registration, which probably still has about $14M left on it.